Improvement of Type 2 Diabetes in a Lung Cancer Patient Treated With Erlotinib
Author:
Affiliation:
1. From the Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
Publisher
American Diabetes Association
Subject
Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine
Link
https://diabetesjournals.org/care/article-pdf/29/7/1711/656450/zdc00706001711.pdf
Reference5 articles.
1. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L, the National Cancer Institute of Canada Clinical Trials Group: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132, 2005
2. Shah NT, Kris MG, Pao W, Tyson LB, Pizzo BM, Heinemann MH, Ben-Porat L, Sachs DL, Heelan RT, Miller VA: Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 23:165–174, 2005
3. Stamos J, Sliwkoski MX, Eingenbrot C: Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 277:46265–46272, 2002
4. Saltiel AR, Kahn CR: Insulin signaling and the regulation of glucose and lipid metabolism. Nature 414:799–806, 2001
5. Veneri D, Franchini M, Bonora E: Imatinib and regression of type 2 diabetes (Letter). N Engl J Med 352:1049–1050, 2005
Cited by 40 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Targeting the epidermal growth factor receptor (EGFR/ErbB) for the potential treatment of renal pathologies;Frontiers in Pharmacology;2024-08-21
2. Improvement of Hyperglycemia Following Treatment with Erlotinib;Endocrine;2024-08-09
3. Membrane protease prostasin promotes insulin secretion by regulating the epidermal growth factor receptor pathway;Scientific Reports;2023-06-05
4. Kinase inhibitors for cancer alter metabolism, blood glucose, and insulin;Journal of Endocrinology;2022-12
5. Future treatment of Diabetes – Tyrosine Kinase inhibitors;Journal of Diabetes & Metabolic Disorders;2022-12-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3